Your browser doesn't support javascript.
Just how common is TTS after a second dose of the ChAdOx1 nCov-19 vaccine? - Authors' reply.
Bhuyan, Prakash; Medin, Jennie; da Silva, Hugo Gomes; Yadavalli, Madhavi; Nord, Magnus.
  • Bhuyan P; Clinical Development, Late-stage Development, Respiratory and Immunology, BioPharmaceuticals Research and Development, AstraZeneca, Gaithersburg, MD, USA.
  • Medin J; BioPharmaceuticals Medical, AstraZeneca, Gothenburg SE431 83, Sweden.
  • da Silva HG; BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
  • Yadavalli M; Patient Safety, Chief Medical Office, Research and Development, AstraZeneca, Gaithersburg, MD, USA.
  • Nord M; Patient Safety, Chief Medical Office, Research and Development, AstraZeneca, Gothenburg SE431 83, Sweden. Electronic address: magnus.nord@astrazeneca.com.
Lancet ; 398(10313): 1801-1802, 2021 11 13.
Article in English | MEDLINE | ID: covidwho-1510436

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines Topics: Vaccines Limits: Humans Language: English Journal: Lancet Year: 2021 Document Type: Article Affiliation country: S0140-6736(21)02317-5

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines Topics: Vaccines Limits: Humans Language: English Journal: Lancet Year: 2021 Document Type: Article Affiliation country: S0140-6736(21)02317-5